Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.54 |
| ▸ | MEN1 | O00255 | 8/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL85230 | 0.92 | MAPT (0.57) | MAPTALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL2941831 | 0.84 | HTT (0.59) | MAPTALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL9581284 | 0.81 | MAPT (0.56) | MAPTALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL1429699 | 0.80 | MEN1 (0.65) | MAPTALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL853676 | 0.80 | MEN1 (0.65) | MAPTALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL12916012 | 0.79 | MAPT (0.62) | MAPTALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL13216550 | 0.79 | ALDH1A1 (0.55) | MAPTALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL2942955 | 0.79 | ALDH1A1 (0.76) | MAPTALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL2681754 | 0.79 | KMT2A (0.44) | MAPTALDH1A1KMT2AMEN1HTT | |
| SCHEMBL85930 | 0.79 | MAPT (0.49) | MAPTALDH1A1KMT2AMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3737671-B1 | PROCESS FOR THE PREPARATION OF 4-(4-AMINOPHENYL)MORPHOLIN-3-ONE | RICHTER GEDEON NYRT (HU) | 2021-11-17 | — | — | EP | claimed |
| EP-3737671-A1 | PROCESS FOR THE PREPARATION OF 4-(4-AMINOPHENYL)MORPHOLIN-3-ONE | Richter Gedeon Nyrt. (HU) | 2020-11-18 | — | — | EP | claimed |
| EP-3737671-A1 | PROCESS FOR THE PREPARATION OF 4-(4-AMINOPHENYL)MORPHOLIN-3-ONE | Richter Gedeon Nyrt. (HU) | 2020-11-18 | — | — | EP | disclosed |
| EP-3737671-A1 | PROCESS FOR THE PREPARATION OF 4-(4-AMINOPHENYL)MORPHOLIN-3-ONE | Richter Gedeon Nyrt. (HU) | 2020-11-18 | — | — | EP | disclosed |
| WO-2019138362-A1 | PROCESS FOR THE PREPARATION OF 4-(4-AMINOPHENYL)MORPHOLIN-3-ONE | RICHTER GEDEON NYRT. (HU) | 2019-07-18 | — | — | WO | disclosed |
| CN-103804221-A | Preparation method of 4-(4-amino phenyl)-3-morpholone and intermediate of 4-(4-amino phenyl)-3-morpholone | HUBEI XUNDA PHARMACEUTICAL CO LTD | 2014-05-21 | — | — | CN | disclosed |
| CN-102603665-A | Synthesis method of 4-(4-aminophenyl)-3-morpholone | BEIJING GUANHONG TECHNOLOGY GROUP CO LTD | 2012-07-25 | — | — | CN | disclosed |
| US-20100210864-A1 | PROCESS FOR THE PREPARATION OF N-ARYLMORPHOLINONES | DORSCH DIETER | 2010-08-19 | — | — | US | disclosed |
| US-20100210864-A1 | PROCESS FOR THE PREPARATION OF N-ARYLMORPHOLINONES | DORSCH DIETER | 2010-08-19 | — | — | US | disclosed |
| US-20100210864-A1 | PROCESS FOR THE PREPARATION OF N-ARYLMORPHOLINONES | DORSCH DIETER | 2010-08-19 | — | — | US | disclosed |
| US-7687624-B2 | Process for the production of N-arylmorpholinones | MERCK PATENT GMBH (DE) | 2010-03-30 | — | — | US | disclosed |
| US-7687624-B2 | Process for the production of N-arylmorpholinones | MERCK PATENT GMBH (DE) | 2010-03-30 | — | — | US | disclosed |
| US-7687624-B2 | Process for the production of N-arylmorpholinones | MERCK PATENT GMBH (DE) | 2010-03-30 | — | — | US | disclosed |
| EP-1654240-B1 | METHOD FOR PRODUCTION OF N-ARYL MORPHOLINONES | MERCK PATENT GMBH (DE) | 2006-11-02 | — | — | EP | disclosed |
| US-20060217550-A1 | One pot process; cyclization; 4-(4-nitrophenyl)-3-oxomorpholine; Factor Xa inhibitors; , myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and claudicatio intermittens | MERCK PATENT GMBH (DE) | 2006-09-28 | — | — | US | disclosed |
| EP-1654240-A1 | METHOD FOR PRODUCTION OF N-ARYL MORPHOLINONES | MERCK PATENT GmbH (DE) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005016899-A1 | METHOD FOR PRODUCTION OF N-ARYL MORPHOLINONES | MERCK PATENT GMBH (DE) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210864-A1 | PROCESS FOR THE PREPARATION OF N-ARYLMORPHOLINONES | CYP1A1, CYP1B1, OPRM1 | MAPT 1388/4885ALDH1A1 264/4885POLB 4031/4885 |
| US-20060217550-A1 | One pot process; cyclization; 4-(4-nitrophenyl)-3-oxomorpholine; Factor Xa inhibitors; , myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and claudicatio intermittens | PLAT, PCSK9, SERPINE1 | MAPT 4446/4885ALDH1A1 2931/4885POLB 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.